AstraZeneca PLC / Neurimmune AG (NI006 license)

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

150K US cases/yr · $3.3B Global tafamidis (Vyndaqel/Vyndamax) 2023 sales as proxy for current ATTR-CM market

Disease Overview

Transthyretin amyloid cardiomyopathy is a progressive, infiltrative cardiomyopathy caused by misfolded transthyretin (TTR) protein depositing in the myocardium, leading to restrictive heart failure, conduction disease, arrhythmias, and death typically within 2-5 years of symptomatic diagnosis if untreated. The disease has two forms: hereditary (variant ATTR, vATTR-CM) driven by autosomal dominant mutations in the TTR gene, and the far more common wild-type form (wtATTR-CM), historically considered a disease of older men but increasingly recognized in women and across ethnicities as non-invasive imaging diagnosis using technetium pyrophosphate scintigraphy supplants endomyocardial biopsy. U.S. epidemiology is widely under-diagnosed; current modeling places prevalence at roughly 150,000-300,000 patients with diagnosis penetration well under 25%. Pfizer's Vyndaqel/Vyndamax (tafamidis) opened the category as a TTR stabilizer in 2019, and BridgeBio's Attruby (acoramidis) won FDA approval in late 2024, shifting the competitive frame from monotherapy stabilization toward stabilizer plus silencer or depleter combinations. Cardiology, heart failure, and amyloidosis specialists drive prescribing through cardiac amyloidosis centers of excellence which anchor referral and infusion logistics, with payer coverage well established but utilization management increasingly aggressive on combination regimens.

Competitive Landscape

The ATTR-CM landscape has evolved into a three-modality competitive arena. TTR stabilizers are the entrenched standard of care, led by Vyndaqel/Vyndamax (tafamidis, Pfizer), with Attruby (acoramidis, BridgeBio) approved in November 2024 on ATTRibute-CM data showing improved hierarchical composite outcomes versus tafamidis in cross-trial comparison. TTR silencers are advancing rapidly into the cardiomyopathy indication: Amvuttra (vutrisiran, Alnylam) won an ATTR-CM label expansion in March 2025 on HELIOS-B data; Wainua (eplontersen, Ionis/AstraZeneca) reads out Phase 3 CARDIO-TTRansform in 2025. The third class — TTR depleters targeting already-deposited amyloid fibrils — is what NI006 brings: a passive immunotherapy designed to clear pre-existing cardiac amyloid burden rather than only halt new deposition, addressing reverse-remodeling rather than disease stabilization. NI006 (later renamed coramitug/eldotrasur) Phase 1b suggested cardiac functional improvement on biomarkers and scintigraphy, putting AstraZeneca/Alexion in position to be the first depleter approved if the Phase 3 CARES/HERMES program reads out positively against a silencer or stabilizer backbone, creating combination versus monotherapy decision points for cardiologists.